As of November 7, 2026, Vaxcyte, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 23, 2026 to September 3, 2026, naming 2 appointments and 2 departures. The latest filing names Heath Lukatch, leaving (Form 8-K, September 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vaxcyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-03
- · In / out: Out · Person: Heath Lukatch · Effective: 2026-07-16 · 8-K, 2026-07-15
- · In / out: Out · Person: Jacks Lee · Effective: 2026-06-17 · 8-K, 2026-06-23
Vaxcyte, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-23 to 2026-09-03. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Vaxcyte, Inc. files it.
Also on the record for Vaxcyte, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 9.6% of the class | 5%+ stakes | Source |
| November 6, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 11.6% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 12.1% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 0.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 14.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 11.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 8.9% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.4% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.03% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 8.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 6.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vaxcyte, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vaxcyte, Inc. and the records around it.
Vaxcyte, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Vaxcyte, Inc.
Get an email when Vaxcyte, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vaxcyte, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vaxcyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vaxcyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-03 | Reported | not named in the filing | 8-K, 2026-09-03 | ||
| 2026-07-15 | Out | 2026-07-16 | 8-K, 2026-07-15 | ||
| 2026-07-15 | In | Director | 2026-07-16 | 8-K, 2026-07-15 | |
| 2026-06-23 | Out | 2026-06-17 | 8-K, 2026-06-23 | ||
| 2026-06-23 | In | Director | 8-K, 2026-06-23 |
Who leads Vaxcyte, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John Markels, appointed, effective 2026-07-16 (filed 2026-07-15).
New leaders reset buying decisions — get the Full Report on Vaxcyte, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Vaxcyte, Inc., with the record behind each one.
Find candidates like Director at Vaxcyte, Inc.Every change, in the filing's words
Reported
On August 31, 2026, Vaxcyte, Inc. (the "Company") appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.
- Mikhail Eydelman continues to serve as Senior Vice President, General Counsel.
Departing: Heath Lukatch, effective 2026-07-16
On July 13, 2026, Heath Lukatch notified the Board of Directors (the "Board") of Vaxcyte, Inc. ("the "Company") of his retirement from the Board, effective as of July 16, 2026.
Appointed: John Markels, Director, effective 2026-07-16
Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.
- Dr. Lukatch's retirement was not the result of any disagreement or dispute with the Company.
- The Company thanks Dr. Lukatch for his considerable contributions over more than eight years of Board service.
- Dr. Markels' term will expire at the Company's annual meeting of stockholders in 2028.
- The Board also appointed Dr. Markels to serve as a member of the Audit Committee and Compensation Committee of the Board.
- The Board has determined that Dr. Markels qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards.
- The Company has entered into its standard form of indemnification agreement with Dr. Markels.
Departing: Jacks Lee, effective 2026-06-17
On June 17, 2026, Jacks Lee notified the Board of Directors (the "Board") of Vaxcyte, Inc. ("the "Company") of his retirement from the Board, effective as of June 17, 2026.
Appointed: Moncef Slaoui, Director
On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately.
- Mr. Lee's retirement was not the result of any disagreement or dispute with the Company.
- The Company thanks Mr. Lee for his considerable contributions over the course of his Board service.
- Effective upon his retirement, Mr. Lee entered into a consulting agreement with the Company pursuant to which he will serve as a consultant to the Company on matters relating to global strategic supply and manufacturing operations.
- Dr. Slaoui's term will expire at the Company's annual meeting of stockholders in 2028.
- The Board has determined that Dr. Slaoui qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards.
- The Company has entered into its standard form of indemnification agreement with Dr. Slaoui.
Tools for this story
Each opens in a new tab, filled in for Vaxcyte, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.